X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (950) 950
animals (717) 717
index medicus (682) 682
ether-a-go-go potassium channels - antagonists & inhibitors (678) 678
erg1 potassium channel (579) 579
ether-a-go-go potassium channels - metabolism (436) 436
pharmacology & pharmacy (318) 318
herg (297) 297
chemistry, medicinal (281) 281
potassium channel blockers - pharmacology (258) 258
structure-activity relationship (251) 251
ether-a-go-go potassium channels - genetics (241) 241
patch-clamp techniques (235) 235
dose-response relationship, drug (224) 224
potassium channels (210) 210
rats (199) 199
ether-a-go-go potassium channels (195) 195
cell line (189) 189
long qt syndrome (186) 186
male (178) 178
female (173) 173
potassium channel (171) 171
mice (162) 162
hek293 cells (137) 137
arrhythmia (132) 132
chemistry, organic (128) 128
ether-a-go-go potassium channels - chemistry (124) 124
potassium channels, voltage-gated (120) 120
cardiac-arrhythmia (118) 118
models, molecular (117) 117
action potentials - drug effects (115) 115
cricetinae (113) 113
k+ channel (113) 113
cho cells (111) 111
molecular structure (111) 111
drugs (107) 107
electrophysiology (107) 107
ether-a-go-go potassium channels - physiology (107) 107
ion channels (103) 103
cation transport proteins (102) 102
torsade-de-pointes (100) 100
cardiac & cardiovascular systems (96) 96
analysis (95) 95
biochemistry & molecular biology (95) 95
inhibitory concentration 50 (92) 92
long qt syndrome - chemically induced (92) 92
guinea pigs (91) 91
dogs (90) 90
i-kr (89) 89
drug design (88) 88
piperidines - pharmacology (88) 88
drug discovery (87) 87
mutation (87) 87
potassium channel blockers - chemistry (86) 86
protein binding (86) 86
dna-binding proteins (83) 83
transfection (83) 83
trans-activators (82) 82
cricetulus (81) 81
membrane potentials - drug effects (79) 79
transcriptional regulator erg (79) 79
molecular determinants (77) 77
kinetics (76) 76
physiology (75) 75
block (74) 74
cells, cultured (74) 74
ether-a-go-go potassium channels - drug effects (74) 74
torsades-de-pointes (74) 74
toxicology (73) 73
electrocardiography (72) 72
anti-arrhythmia agents - pharmacology (70) 70
channel (70) 70
in vitro techniques (70) 70
k+ channels (70) 70
prolongation (68) 68
xenopus laevis (67) 67
long-qt syndrome (66) 66
rats, sprague-dawley (66) 66
inhibition (65) 65
qt interval prolongation (65) 65
computer simulation (63) 63
myocytes, cardiac - drug effects (63) 63
cardiovascular diseases (62) 62
discovery (62) 62
pyridines - pharmacology (62) 62
quantitative structure-activity relationship (61) 61
binding (59) 59
heart - drug effects (59) 59
herg channel (59) 59
pharmacology (59) 59
xenopus oocytes (59) 59
binding sites (58) 58
xenopus (58) 58
cell biology (57) 57
long qt syndrome - genetics (57) 57
time factors (57) 57
article (56) 56
potassium channels - metabolism (56) 56
congenital, hereditary, and neonatal diseases and abnormalities (55) 55
cells (54) 54
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cardiovascular Research, ISSN 0008-6363, 7/2011, Volume 91, Issue 1, pp. 53 - 61
Journal Article
Science, ISSN 0036-8075, 1/2010, Volume 327, Issue 5963, pp. 348 - 351
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 11/2014, Volume 96, Issue 5, pp. 549 - 558
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 01/2014, Volume 171, Issue 1, pp. 92 - 106
Background and Purpose Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with an increased risk for stroke, heart failure and... 
atrial fibrillation | Kv1.5 | electrophysiology | resveratrol | ion channels | pharmacology | 1.5 | ACTIVATED PROTEIN-KINASE | POTASSIUM CHANNELS | K+ CURRENT | HEART-FAILURE | THERAPEUTIC IMPLICATIONS | ARRIVE GUIDELINES | K(v)1 | CARDIAC-HYPERTROPHY | PHARMACOLOGY & PHARMACY | OUTWARD CURRENT | DYSFUNCTION | CALORIE RESTRICTION | Anti-Arrhythmia Agents - pharmacology | Humans | Middle Aged | Ether-A-Go-Go Potassium Channels - metabolism | Myocardial Contraction - drug effects | Male | NAV1.5 Voltage-Gated Sodium Channel - metabolism | Stilbenes - pharmacology | Atrial Fibrillation - physiopathology | ERG1 Potassium Channel | Action Potentials | Dose-Response Relationship, Drug | Transfection | NAV1.5 Voltage-Gated Sodium Channel - drug effects | HEK293 Cells | Kv1.5 Potassium Channel - genetics | G Protein-Coupled Inwardly-Rectifying Potassium Channels - metabolism | Adult | NAV1.5 Voltage-Gated Sodium Channel - genetics | G Protein-Coupled Inwardly-Rectifying Potassium Channels - antagonists & inhibitors | Potassium Channel Blockers - pharmacology | Disease Models, Animal | Animals, Newborn | Excitation Contraction Coupling - drug effects | Atrial Fibrillation - drug therapy | NFATC Transcription Factors - metabolism | Rats | Sodium Channel Blockers - pharmacology | Antioxidants - pharmacology | Ether-A-Go-Go Potassium Channels - genetics | G Protein-Coupled Inwardly-Rectifying Potassium Channels - genetics | Rats, Sprague-Dawley | Ether-A-Go-Go Potassium Channels - antagonists & inhibitors | Atrial Fibrillation - metabolism | Animals | Myocytes, Cardiac - drug effects | Dogs | Kv1.5 Potassium Channel - metabolism | Myocytes, Cardiac - metabolism | Kv1.5 Potassium Channel - antagonists & inhibitors | Aged | NFATC Transcription Factors - antagonists & inhibitors | Heart failure | Heart | Antioxidants | Analysis | Atrial fibrillation | Mortality | Resveratrol | Chemical properties | Genetic transcription | Drug therapy | Research Papers
Journal Article